ALK-Abello A/S (AKBLF)
38.89
0.00 (0.00%)
USD |
OTCM |
Jun 10, 16:00
ALK-Abello EPS Diluted (Quarterly) : 0.3088 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.3088 |
| December 31, 2025 | 0.1871 |
| September 30, 2025 | 0.2219 |
| June 30, 2025 | 0.1803 |
| March 31, 2025 | 0.2256 |
| December 31, 2024 | 0.1094 |
| September 30, 2024 | 0.141 |
| June 30, 2024 | 0.1311 |
| March 31, 2024 | 0.1527 |
| December 31, 2023 | 0.0911 |
| September 30, 2023 | 0.0772 |
| June 30, 2023 | 0.0436 |
| March 31, 2023 | 0.1063 |
| December 31, 2022 | 0.0484 |
| September 30, 2022 | 0.0311 |
| June 30, 2022 | 0.0272 |
| March 31, 2022 | 0.1116 |
| December 31, 2021 | 0.0531 |
| September 30, 2021 | 0.0268 |
| June 30, 2021 | -0.0156 |
| March 31, 2021 | 0.0931 |
| December 31, 2020 | -0.0227 |
| September 30, 2020 | -0.0144 |
| June 30, 2020 | -0.0068 |
| March 31, 2020 | 0.0581 |
| Date | Value |
|---|---|
| December 31, 2019 | -0.0197 |
| September 30, 2019 | -0.0096 |
| June 30, 2019 | -0.047 |
| March 31, 2019 | 0.0315 |
| December 31, 2018 | -0.1026 |
| September 30, 2018 | -0.0221 |
| June 30, 2018 | -0.0125 |
| March 31, 2018 | 0.0182 |
| December 31, 2017 | -0.1258 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | -0.0008 |
| March 31, 2017 | 0.0015 |
| December 31, 2016 | 0.0268 |
| September 30, 2016 | 0.03 |
| June 30, 2016 | 0.0531 |
| March 31, 2016 | 0.0917 |
| December 31, 2015 | 0.1034 |
| September 30, 2015 | 0.0471 |
| June 30, 2015 | 0.0403 |
| March 31, 2015 | 0.0682 |
| December 31, 2014 | 0.0139 |
| September 30, 2014 | 0.0234 |
| June 30, 2014 | 0.0288 |
| March 31, 2014 | 0.1001 |
| December 31, 2013 | 0.0365 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Novo Nordisk A/S | 1.709 |
| H. Lundbeck A/S | 0.2616 |
| AstraZeneca PLC | 0.9849 |
| ANI Pharmaceuticals, Inc. | 1.276 |
| Corcept Therapeutics, Inc. | -0.2988 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 68.43M |
| Revenue (Quarterly) | 277.34M |
| Total Expenses (Quarterly) | 208.91M |
| Enterprise Value | 8.442B |
| Gross Profit Margin (Quarterly) | 69.34% |
| Profit Margin (Quarterly) | 24.68% |
| Earnings Yield | 2.31% |
| Operating Earnings Yield | 3.16% |
| Normalized Earnings Yield | 2.310 |